LAMISIL AT

Adults and children over 16 years of age Lamisil AT 1% Cream is applied once daily. Duration and frequency of treatment Duration of treatment is one week for tinea pedis and tinea cruris. Relief of clinical symptoms usually occurs within a few days.

Irregular use or premature discontinuation of treatment carries the risk of recurrence. If there are no signs of improvement after two weeks, the diagnosis should be verified by a physician.

Dosing in special populations:

Paediatric population The experience with topical Lamisil AT 1% Cream in children is still limited and its use in children under 16 years cannot therefore be recommended. Elderly patients There is no evidence to suggest that elderly patients require different dosages or experience side-effects different to those of younger patients.

Method of administration For cutaneous use. The affected area should be cleaned and dried thoroughly before application of Lamisil AT 1% Cream. The cream should be applied to the affected skin and surrounding area in a thin layer and rubbed in lightly.

In the case of intertriginous infections (interdigital, intergluteal, inguinal) the application may be covered with a gauze strip, especially at night.

Local symptoms such as pruritis, skin exfoliation, application site pain, application site irritation, pigmentation disorder, skin burning sensation, erythema and scab may occur at the site of application. These minor symptoms must be distinguished from hypersensitivity reactions such as widespread pruritis, rash, bullous eruptions and hives, which are reported in sporadic cases but require discontinuation.

In case of accidental contact with the eyes, terbinafine hydrochloride may be irritating to the eyes. In rare cases the underlying fungal infection may be aggravated. Adverse reactions are listed below by system organ class and frequency.

Frequencies are defined as: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000), or not known (can not to be estimated from available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.

Immune system disorders Frequency not known:

Hypersensitivity Eye disorders Rare: Eye irritation Skin and subcutaneous tissue disorders Common: Skin exfoliation, pruritus Uncommon: Skin lesion, scab, skin disorder, pigmentation disorder, erythema, skin burning sensation Rare: Dry skin, dermatitis contact, eczema Frequency not known: Rash General disorders and administration site conditions Uncommon: Pain, application site pain, application site irritation Rare: Condition aggravated Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.

It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard.

Lamisil AT 1% cream is for external use only. Should be used with caution in patients with lesions where alcohol could be irritating. Should not be used on the face. Contact with the eyes should be avoided. May be irritating to the eyes.

In case of accidental contact with the eyes, rinse the eyes thoroughly with running water. Should be kept out of the sight and reach of children. This medicine contains 36 mg benzyl alcohol in each daily dosage which is equivalent to 10 mg/g.

Benzyl alcohol may cause allergic reactions. g. contact dermatitis).

1.